DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
BQ-123 is an investigational drug.
There have been 14 clinical trials for BQ-123. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2005.
The most common disease conditions in clinical trials are Coronary Artery Disease, Coronary Disease, and Myocardial Ischemia. The leading clinical trial sponsors are Medical University of Vienna, Brigham and Women's Hospital, and University of Edinburgh.
Recent Clinical Trials for BQ-123
|The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction||The University of Texas at Arlington||Phase 1|
|Mechanisms of Cerebrovascular Control||University of Wisconsin, Madison||Phase 1|
|Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure||University of Utah||Phase 0|